Try
BIOGEN INC.
BIIBUnited States
87 filed reports · 677 financial concepts · 2 earnings calls · 4 media appearances
Filed reports
87 reports · Jun 2014 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 246 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Current · 8-KSEC EDGAR | 38 | 254 | Jun 2014 to Jun 2026 |
| Quarterly · 10-QSEC EDGAR | 37 | 9,099 | Jun 2014 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 12 | 9,031 | Dec 2014 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 8-K | Jun 30, 2026 | Jul 29, 2026 | 2 | Open |
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Jul 29, 2026 | 592 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | Apr 29, 2026 | 6 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | Apr 29, 2026 | 421 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 6, 2026 | 4 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 6, 2026 | 1,569 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Jan 14, 2026 | 2 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Oct 30, 2025 | 473 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Jul 31, 2025 | 264 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Jul 7, 2025 | 2 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 1, 2025 | 251 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 12, 2025 | 703 | Open |
Financial data
677 concepts · 18,384 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial627 concepts · 14,440 facts · Dec 2011 to Jul 2026
- Accumulated other comprehensive income loss net of tax69 · Dec 2011 to Jun 2026
- Net income loss68 · Dec 2012 to Jun 2026
- Profit loss68 · Dec 2012 to Jun 2026
- Revenue68 · Dec 2012 to Jun 2026
- Allocated share based compensation expense net of tax67 · Dec 2012 to Jun 2026
- Comprehensive income net of tax67 · Dec 2012 to Jun 2026
- Costs and expenses67 · Dec 2012 to Jun 2026
- Employee service share based compensation allocation of recognized period costs capitalized amount67 · Dec 2012 to Jun 2026
- Employee service share based compensation tax benefit from compensation expense67 · Dec 2012 to Jun 2026
- Foreign currency transaction gain loss before tax67 · Dec 2012 to Jun 2026
- Gain loss on foreign currency derivative instruments not designated as hedging instruments67 · Dec 2012 to Jun 2026
- Income tax expense benefit67 · Dec 2012 to Jun 2026
- Interest expense (US GAAP)67 · Dec 2012 to Jun 2026
- Investment income interest67 · Dec 2012 to Jun 2026
- Other comprehensive income loss foreign currency transaction and translation adjustment net of tax67 · Dec 2012 to Jun 2026
- Other comprehensive income loss net of tax67 · Dec 2012 to Jun 2026
- Other comprehensive income loss pension and other postretirement benefit plans adjustment net of tax67 · Dec 2012 to Jun 2026
- Other nonoperating income expense67 · Dec 2012 to Jun 2026
- Research and development expense excluding acquired in process cost67 · Dec 2012 to Jun 2026
- Selling general and administrative expense67 · Dec 2012 to Jun 2026
- Share-based compensation expense included in total cost and expense67 · Dec 2012 to Jun 2026
- Deferred income tax expense benefit66 · Dec 2012 to Jun 2026
- Depreciation depletion and amortization66 · Dec 2012 to Jun 2026
- Increase decrease in accrued liabilities66 · Dec 2012 to Jun 2026
Product27 concepts · 3,265 facts · Dec 2012 to Jun 2026
- Revenue3,132 · Dec 2012 to Jun 2026
- LUNSUMIO25 · Dec 2014 to Jun 2026
- OCREVUS22 · Dec 2015 to Dec 2025
- TECFIDERA9 · Jun 2020 to Dec 2022
- Amortization of intangible assets7 · Mar 2017 to Dec 2018
- Cost of goods and services sold (US GAAP)7 · Mar 2018 to Dec 2023
- Research and development expense7 · Mar 2019 to Dec 2023
- Zorevunersen7 · Dec 2021 to Dec 2025
- Inventory write down6 · Dec 2021 to Mar 2023
- New Anti Cd206 · Dec 2018 to Dec 2023
- GAZYVA5 · Dec 2014 to Dec 2025
- Impairment of intangible assets finitelived4 · Mar 2017 to Dec 2018
- R&D Expense4 · Dec 2022 to Sep 2023
- Finite lived intangible assets period increase decrease3 · Mar 2016 to Dec 2019
- Income loss from equity method investments3 · Dec 2021 to Dec 2023
- Research and development expense excluding acquired in process cost3 · Dec 2015 to Mar 2018
- Mosunetuzumab2 · Dec 2021 to Dec 2022
- Other sales revenue net2 · Mar 2017 to Mar 2018
- Selling and marketing expense (US GAAP)2 · Dec 2022 to Dec 2023
- Unrecognized tax benefits period increase decrease2 · Dec 2017
- Asset impairment charges1 · Dec 2017
- Contract manufacturing revenue1 · Jun 2020
- Cost of goods sold1 · Mar 2018
- Deferred tax liability recognized1 · Dec 2013
Segment5 concepts · 286 facts · Dec 2012 to Jun 2026
- Revenue226 · Dec 2012 to Jun 2026
- Cost of goods and services sold (US GAAP)28 · Dec 2022 to Jun 2026
- Net income loss14 · Dec 2022 to Jun 2026
- Segment reporting other item amount14 · Dec 2022 to Jun 2026
- Selling general and administrative expense4 · Dec 2022 to Dec 2025
Guidance11 concepts · 264 facts · Jul 2014 to Jul 2026
- EPS (Diluted) Guidance80 · Jul 2014 to Apr 2026
- Revenue Guidance36 · Jan 2016 to Jul 2022
- Revenue Growth Guidance30 · Jul 2014 to Jul 2026
- EPS (Diluted) Guidance (Adjusted (non-GAAP))28 · Oct 2014 to Oct 2020
- Effective Tax Rate Guidance26 · Jan 2018 to Apr 2026
- Net Income Guidance18 · Jul 2014 to Oct 2020
- Net Income Guidance (Adjusted (non-GAAP))14 · Jan 2015 to Oct 2020
- Effective Tax Rate Guidance (Adjusted (non-GAAP))12 · Jan 2018 to Jul 2020
- Capital Expenditures Guidance8 · Feb 2021 to Oct 2021
- Operating Income Growth Guidance6 · Feb 2024 to Aug 2024
- Operating Margin Guidance6 · Feb 2024 to Aug 2024
Geography7 concepts · 129 facts · Dec 2012 to Mar 2018
- Revenue37 · Dec 2012 to Mar 2018
- Other sales revenue net29 · Dec 2012 to Dec 2017
- Accounts Receivable, Net21 · Dec 2013 to Dec 2015
- Revenues from unconsolidated joint business20 · Dec 2012 to Dec 2015
- Revenues from anti-CD20 therapeutic programs19 · Dec 2014 to Dec 2017
- Litigation settlement expense2 · Dec 2016
- Spain1 · Mar 2014
Segments
3,680 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or servicesrt:ProductOrServiceAxis53 members · 3,094 facts
- Product174 · Dec 2016 to Jun 2026
- BENEPALI142 · Dec 2016 to Jun 2026
- FAMPYRA142 · Dec 2016 to Jun 2026
- FLIXABI142 · Dec 2016 to Jun 2026
- Interferon142 · Dec 2016 to Jun 2026
- SPINRAZA142 · Dec 2016 to Jun 2026
- Tysabri Product142 · Dec 2016 to Jun 2026
- Biosimilars132 · Dec 2016 to Jun 2026
- IMRALDI132 · Dec 2016 to Jun 2026
- MS Product Revenues132 · Dec 2016 to Jun 2026
- Fumarate111 · Dec 2018 to Jun 2026
- FUMADERM91 · Dec 2016 to Dec 2022
- TECFIDERA91 · Dec 2018 to Jun 2026
- VUMERITY91 · Dec 2017 to Jun 2026
- Revenuesfromanticd20therapeuticprograms84 · Dec 2016 to Jun 2026
- AVONEX81 · Dec 2020 to Jun 2026
- BYOOVIZ81 · Dec 2020 to Jun 2026
- PLEGRIDY81 · Dec 2020 to Jun 2026
- Product And Service Other76 · Dec 2016 to Jun 2026
- FUMADERM And ADUHELM66 · Mar 2022 to Jun 2026
- ADUHELM63 · Dec 2019 to Dec 2023
- QALSODY57 · Dec 2021 to Jun 2026
- Rare Disease Product Revenue57 · Dec 2021 to Jun 2026
- SKYCLARYS57 · Dec 2021 to Jun 2026
- Tecfidera53 · Dec 2016 to Mar 2020
- ZINBRYTA53 · Dec 2016 to Dec 2020
- TOFIDENCE51 · Dec 2022 to Jun 2026
- ZURZUVAE51 · Dec 2022 to Jun 2026
- Contract Manufacturing And Other Revenue48 · Dec 2016 to Jun 2026
- Royalty47 · Dec 2016 to Jun 2026
- Other Products30 · Jun 2023 to Jun 2026
- Royalty Attributed To OCREVUS24 · Dec 2020 to Jun 2026
- ALPROLIX22 · Dec 2016 to Dec 2019
- ELOCTATE22 · Dec 2016 to Dec 2019
- Contract Manufacturing Royalty And Other Revenue20 · Dec 2021 to Dec 2025
- GAZYVA18 · Dec 2018 to Dec 2025
- OCREVUS16 · Dec 2018 to Dec 2025
- Other15 · Dec 2021 to Dec 2025
- Alzheimers Collaboration14 · Dec 2022 to Jun 2026
- LEQEMBI Collaboration13 · Mar 2022 to Jun 2026
- Hemophilia Products12 · Dec 2016 to Dec 2019
- Mosunetuzumab12 · Dec 2021 to Dec 2024
- Product12 · Dec 2023 to Dec 2025
- Contract manufacturing royalty and other revenue9 · Dec 2023 to Dec 2025
- Revenuesfromanticd20therapeuticprograms9 · Dec 2023 to Dec 2025
- LUNSUMIO6 · Mar 2025 to Jun 2026
- New Anti Cd206 · Dec 2018 to Dec 2023
- Specialized Immunology6 · Jun 2025 to Jun 2026
- SYFOVRE6 · Jun 2025 to Jun 2026
- Aduhelm4 · Dec 2022 to Sep 2023
- EMPAVELI4 · Jun 2025 to Jun 2026
- BAN24011 · Mar 2019
- Elenbecestat Collaboration1 · Mar 2019
Statement business segments3 members · 286 facts
- Reportable146 · Dec 2022 to Jun 2026
- Rest Of World70 · Dec 2012 to Dec 2017
- US70 · Dec 2012 to Dec 2017
Product or serviceus-gaap:ProductOrServiceAxis21 members · 171 facts
- Tecfidera18 · Dec 2012 to Mar 2018
- ZINBRYTA17 · Dec 2013 to Mar 2018
- ELOCTATE12 · Dec 2012 to Mar 2018
- FAMPYRA12 · Dec 2012 to Mar 2018
- FUMADERM12 · Dec 2012 to Mar 2018
- BENEPALI11 · Dec 2014 to Mar 2018
- Hemophilia Products11 · Dec 2015 to Dec 2017
- FLIXABI10 · Dec 2014 to Mar 2018
- SPINRAZA10 · Dec 2014 to Mar 2018
- GAZYVA7 · Dec 2014 to Dec 2017
- ALPROLIX6 · Mar 2017 to Mar 2018
- ALPROLIX Product6 · Dec 2012 to Dec 2017
- AVONEX6 · Dec 2012 to Dec 2017
- Interferon6 · Mar 2017 to Mar 2018
- PLEGRIDY6 · Dec 2012 to Dec 2017
- Tysabri6 · Dec 2012 to Dec 2017
- Tysabri Product6 · Mar 2017 to Mar 2018
- Ocrelizumab4 · Dec 2015 to Dec 2016
- Contract Manufacturing And Other Revenue2 · Mar 2017 to Mar 2018
- OCREVUS2 · Dec 2017
- Zinbryta1 · Sep 2017
Statement geographical13 members · 129 facts
- US23 · Dec 2012 to Mar 2018
- Asia20 · Dec 2012 to Dec 2017
- Europe20 · Dec 2012 to Dec 2017
- Segment Geographical Groups Of Countries Group Other20 · Dec 2012 to Dec 2017
- DE17 · Dec 2012 to Dec 2016
- Es7 · Dec 2013 to Mar 2015
- Pt7 · Dec 2013 to Mar 2015
- It5 · Dec 2013 to Dec 2014
- IT4 · Jun 2014 to Mar 2017
- Spainand portugal2 · Dec 2014 to Dec 2015
- Rest Of World2 · Mar 2017 to Mar 2018
- ES1 · Mar 2014
- European Union1 · Dec 2016
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary128 claims from 11 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary264 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes10 claims from 1 reports · Dec 2025
- Risk factors80 risks from 2 annual reports · 2024 to 2025
Earnings calls
2 calls · Jul 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Jul 29, 2026
- FY2026 Q1Jul 1, 2026
Executive media
4 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- Conference talks2 · Jun 2024 to Sep 2025
- TV interviews2 · Jan 2023 to Jan 2026
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.